Heart failure associated with sunitinib malate
- 3 April 2008
- Vol. 112 (11), 2500-2508
- https://doi.org/10.1002/cncr.23460
Abstract
BACKGROUND. Sunitinib malate is a novel multitargeted receptor tyrosine kinase inhibitor with established efficacy in the treatment of metastatic renal cell carcinoma and imatinib‐resistant gastrointestinal stromal tumor. This report describes the development of heart failure in cancer patients who received this novel agent. METHODS. A retrospective study was conducted at M. D. Anderson Cancer Center during a 1‐year period on patients who received sunitinib and developed heart failure. RESULTS. During 2006, 6 of 224 (2.7%) patients who received sunitinib developed heart failure (HF) that resulted in substantial morbidity and, in some cases, mortality. Symptomatic heart failure occurred soon after initiation of sunitinib (mean onset 22 days after initiation), was associated with decline in cardiac function and elevations in blood pressure, and was not completely reversible in most patients, even after termination of sunitinib therapy. CONCLUSIONS. These observations suggested that sunitinib‐associated heart failure may represent a potentially serious toxicity and underscore the need for careful monitoring of cardiac function and aggressive control of hypertension in these patients. Studies to elucidate potential mechanisms of heart failure and left ventricular dysfunction resulting from treatment with sunitinib are necessary to develop strategies for prevention and treatment of this complication. Cancer 2008. ©2008 American Cancer Society.This publication has 26 references indexed in Scilit:
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell CarcinomaThe Oncologist, 2007
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialThe Lancet, 2006
- Sunitinib in Patients With Metastatic Renal Cell CarcinomaJama-Journal Of The American Medical Association, 2006
- Atrial Fibrillation and Ventricular DysfunctionCirculation, 2004
- Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated CardiomyopathyNew England Journal of Medicine, 2004
- SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivoBlood, 2003
- Lifetime Risk for Developing Congestive Heart FailureCirculation, 2002
- Independent Risk Factors for Atrial Fibrillation in a Population-Based CohortJama-Journal Of The American Medical Association, 1994
- Hypertension-induced changes of platelet-derived growth factor receptor expression in rat aorta and heart.Hypertension, 1991